Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

NCT02274545 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Influenza A Virus, H7N9 Subtype

Interventions

BIOLOGICAL: H7N9 Anhui 2013/AA ca
BIOLOGICAL: Inactivated subvirion H7N9 vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)